X
[{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AI Therapeutics Announces Significant Progress on LAM-001 and LAM-004 Programs","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AI Therapeutics Announces Start of Phase II Trial of LAM-002A (apilimod dimesylate) for Treatment of COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"EntreChem","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AI Therapeutics Announces the Acquisition of Novel Cancer Drug Candidate EC-8042 (AIT-102)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AI Therapeutics Announces Positive Results from Phase 2a Biomarker-driven Trial of AIT-101 in Patients with C9ORF72 Amyotrophic Lateral Sclerosis (ALS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AI Therapeutics Announces Investigator Initiated Phase 2 Trial at UCSF to Study LAM-001 in Patients With Bronchiolitis Obliterans Syndrome (BOS) Post-Lung Transplant","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AI Therapeutics Announces Initiation of a Phase 2 Clinical Trial of LAM-001 for Treatment of Pulmonary Arterial Hypertension (PAH)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by AI Therapeutics
Filters
Companies By Therapeutic Area
Details:
LAM-001 (sirolimus) is a proprietary, investigational, inhaled formulation of sirolimus, which is investigated in Patients With pulmonary arterial hypertension.
Lead Product(s):
Sirolimus
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: LAM-001
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 31, 2023
Details:
LAM-001 (sirolimus) is a proprietary, investigational, inhaled formulation of sirolimus, which is investigated in Patients With Bronchiolitis Obliterans Syndrome (BOS) Post-Lung Transplant.
Lead Product(s):
Sirolimus
Therapeutic Area: Immunology
Product Name: LAM-001
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 18, 2023
Details:
AIT-101 (apilimod dimesylate) is a potent and highly selective inhibitor of the lipid kinase PIKfyve, which activates the transcription factor TFEB which drives the increased clearance of toxic protein aggregates. It is being investegated for treating C9ORF72 ALS.
Lead Product(s):
Apilimod mesylate
Therapeutic Area: Neurology
Product Name: AIT-101
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 05, 2023
Details:
EC-8042 (redesignated AIT-102), is a targeted cancer therapy that inhibits the activity of SWI/SNF in certain tumors where SWI/SNF is mutated (such as Rhabdoid tumors) and in other tumors where SWI/SNF associates with oncogenic transcription factors.
Lead Product(s):
AIT-102
Therapeutic Area: Oncology
Product Name: AIT-102
Highest Development Status: Preclinical
Product Type: Large molecule
Recipient:
EntreChem
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Acquisition
April 25, 2022
Details:
The randomized, double-blind, placebo-controlled study will enroll up to 142 outpatients to evaluate the safety, tolerability, and efficacy of LAM-002A in reducing viral load in subjects with a confirmed COVID-19.
Lead Product(s):
Apilimod mesylate
Therapeutic Area: Infections and Infectious Diseases
Product Name: LAM-002
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 27, 2020
Details:
The company has made significant recent progress on its four clinical assets and proprietary Guardian Angel™ algorithm.
Lead Product(s):
Sirolimus
Therapeutic Area: Pulmonary/Respiratory Diseases
Product Name: Undisclosed
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 07, 2020